



INDO US
BIO-TECH LIMITED
(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Date: 14th February, 2024

To,
General Manager,
Corporate Relationship,
BSE Limited, P J Tower,
Dalal Street,
Mumbai — 400 001

Sub: Outcome of Board Meeting held on 14th February, 2024, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Scrip Code: 541304

Ref: Indo Us Bio Tech Limited

Dear Sir,

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, 14th February, 2024 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

1. The Board approved unaudited financial results of the company for the quarter ended 31st December, 2023 along with limited review reports obtained from the Auditor of the Company.

The Board Meeting commenced at 16.00 P.M. and concluded at 16:20 P.M.

You are requested to kindly take the same on record.

Thanking you,

For, Indo us Bio Tech Limited

DIMPY
DIVYANGBHAI JOSHI
+05'30'

Digitally signed by DIMPY
DIVYANGBHAI JOSHI
Date: 2024.02.14 16:22:47
+05'30'

Ms. DimpY Joshi
Company Secretary & Compliance officer





INDO US BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Bio-tech Limited

Statement of standalone unaudited financial results for the quarter ended on 31st December 2023

PARTICULARS	Quarter Ended					Year ended 31-03-2023 (Audited)	
	31-12-2023 (Unaudited)		30-09-2023 (Unaudited)		31-12-2022 (Unaudited)		
	31-12-2023 (Unaudited)		31-12-2022 (Unaudited)		31-12-2022 (Unaudited)		
I Income							
Revenue from operations	2,211.37	1,581.37	1,550.27	5,707.01	4,363.51	6,174.48	
Other income	7.70	0.31	0.31	10.86	0.34	2.08	
Total income from operations	2,219.07	1,581.68	1,550.59	5,717.87	4,363.86	6,176.56	
II Expenses							
Purchases	106.92	354.09	27.44	568.62	334.48	526.78	
Production Expenses	1,383.15	1,216.76	1,006.58	3,375.01	2,505.06	4,297.17	
Change in inventories	49.87	(577.95)	113.10	22.58	381.49	(312.39)	
Employee benefit expenses	29.62	35.65	34.58	97.04	101.62	152.50	
Finance costs	37.34	40.92	41.03	115.47	91.59	118.43	
Depreciation and amortization expenses	18.95	21.32	29.19	60.32	61.95	82.59	
Other expenses	217.83	293.50	163.28	661.33	412.58	572.78	
Total expenses	1,843.69	1,384.29	1,415.19	4,900.36	3,888.76	5,437.87	
III Profit/(Loss) before exceptional items and tax	375.39	197.39	135.39	817.51	475.09	738.68	
IV Exceptional items- Prior Period Items							
V Profit/(Loss) before tax	375.39	197.39	135.39	817.51	475.09	738.68	
VI Tax expenses							
a) Current tax	9.00	9.38	1.00	30.00	31.00	33.93	
b) Income tax prior year	0.39	25.38	(2.72)	25.77	(2.72)	(2.41)	
b) Deferred tax	(2.47)	(4.29)	-	(10.97)	-	(16.88)	
Total tax expenses	6.92	30.47	(1.72)	44.80	28.28	14.65	
VII Net Profit/(Loss) for the period/year	368.46	166.92	137.12	772.71	446.82	724.04	
VIII Other comprehensive income (net of tax)							
Items that will not be reclassified to profit or loss:							
i) Remeasurement of post employment benefit obligations	-	-	-	-	-	-	
ii) Income-tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	
Total other comprehensive income							
IX Total comprehensive income for the period/year (VII-VIII)	368.46	166.92	137.12	772.71	446.82	724.04	
X Paid-up equity share capital (face value of Rs.10 per share)	2,005.20	2,005.20	1,002.60	2,005.20	1,002.60	1,002.60	
XI Other equity (excluding revaluation reserve)	4,217.09	3,848.62	3,418.06	4,217.09	3,418.06	4,446.98	
XII EPS in Rs. (Face Value of Rs.10/- each)*							
-Basic	1.84	0.83	1.37	3.85	4.46	7.22	
-Diluted	1.84	0.83	1.37	3.85	4.46	7.22	
-Adjusted	1.84	0.83	0.68	3.85	2.23	3.61	
*not annualised							

Notes

- The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14th February 2024 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.
- The company is dealing in one major product segment, i.e. Seed Cultivation.
- The company has issued bonus share at the ratio 1:1 as on 01st September, 2023.
- The figures have been regrouped/rearranged wherever necessary.

For, **INDO US BIO-TECH LIMITED**

[Signature]
DIRECTOR



**FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS**

[Signature]
GAUTAM NANDAWAT
(Partner)

UDIN: 24032742BKCROP4366


Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

OSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.



E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com

Place: Ahmedabad
Date: 14th February 2024





LIMITED REVIEW REPORT

To,
The Board of Directors
Indo US Bio-Tech Limited
Ahmedabad

1. We have reviewed the accompanying statement of unaudited financial results of Indo US Bio-Tech Limited for the quarter ended 31st December 2023 and year to date results for the period 1st April 2023 to 31st December 2023 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No CIR/CFD/CMD1/44/2019 dated 29th March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of Listing Regulations, to the extent applicable.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat

Partner,

M No: 032742

UDIN: **24032742BKCROP4366**

Place: Chhatrapati Sambhajnagar

Date: 14-02-2024

